Aston University (Birmingham, UK) has announced the installation of the Waters (MA, USA) SELECT SERIES Cyclic™ ion mobility spectrometry mass spectrometer, the first commercial research installation of an instrument of its kind.
Browsing: Advanced therapies
Novel artificial intelligence tool could revolutionize bioanalytical data review for precision drug development
Specialist in artificial intelligence-enabled solutions, Ariadne Software (PA, USA), announces the launch of Red Thread™, an innovative tool that could revolutionize bioanalytical data review for precision drug development.
In a pilot study, researchers from the School of Medicine at the University of Nottingham (UK), report the use of protein microarrays to rapidly screen blood samples for the presence of autoantibodies associated with breast cancer.
Find out what regulatory recommendations exist for bioanalytical support of adeno-associated virus gene therapy development in this Bioanalysis article giving an overview of the current regulatory recommendations as found in FDA and EMA guidance documents.
Researchers from the RIKEN Center for Brain Science (Wako, Japan) have identified that hydrogen sulfide production – as a result of MPST gene expression – was higher in postmortem brains from individuals with schizophrenia compared with unaffected individuals.
In this interview from 3DMedNet, Laura Mercolini (Alma Mater Studiorum, University of Bologna, Italy) discusses how the latest 3D printing techniques and technology are enhancing bioanalytical research: from sampling to sample handling, pretreatment and instrumental analysis.
Scientists from the University of California San Diego (CA, USA) and the University of Alcalá (Madrid, Spain) have reported a pacifier biosensor that could pave the way for future research towards noninvasive saliva biomarker monitoring.
In this feature, we will be investigating chimeric antigen receptor T-cell therapies, their benefits and potential side effects, and what the future may hold for the development of this type of immunotherapy treatment.
In this interview, David Harris (Charles River Laboratories; NC, USA) discusses the current global landscape for cell therapy, associated safety concerns and challenges, and preclinical animal models that are used to evaluate cellular therapies.
Discover more about the development of CAR-T cell therapies, their bioanalytical challenges and specialized antibody reagents that can be ustilized to overcome these in this interview with Michael Schwenkert (Bio-Rad Laboratories; Germany).